| Lattice‐distortion‐enhanced yield strength in a refractory high‐entropy alloy C Lee, Y Chou, G Kim, MC Gao, K An, J Brechtl, C Zhang, W Chen, ... Advanced Materials 32 (49), 2004029, 2020 | 213 | 2020 |
| Phase transformations of HfNbTaTiZr high-entropy alloy at intermediate temperatures SY Chen, Y Tong, KK Tseng, JW Yeh, JD Poplawsky, JG Wen, MC Gao, ... Scripta Materialia 158, 50-56, 2019 | 204 | 2019 |
| Temperature dependence of elastic and plastic deformation behavior of a refractory high-entropy alloy C Lee, G Kim, Y Chou, BL Musicó, MC Gao, K An, G Song, YC Chou, ... Science Advances 6 (37), eaaz4748, 2020 | 182 | 2020 |
| First-principles and machine learning predictions of elasticity in severely lattice-distorted high-entropy alloys with experimental validation G Kim, H Diao, C Lee, AT Samaei, T Phan, M de Jong, K An, D Ma, ... Acta Materialia 181, 124-138, 2019 | 148 | 2019 |
| Composition design of high-entropy alloys with deep sets learning J Zhang, C Cai, G Kim, Y Wang, W Chen npj Computational Materials 8 (1), 89, 2022 | 50 | 2022 |
| Experimental formation enthalpies for intermetallic phases and other inorganic compounds G Kim, SV Meschel, P Nash, W Chen Scientific data 4 (1), 1-11, 2017 | 50 | 2017 |
| The role of solid solutions in iron phosphate-based electrodes for selective electrochemical lithium extraction G Yan, G Kim, R Yuan, E Hoenig, F Shi, W Chen, Y Han, Q Chen, JM Zuo, ... Nature communications 13 (1), 4579, 2022 | 39 | 2022 |
| Elastic behavior of binary and ternary refractory multi-principal-element alloys R Feng, G Kim, D Yu, Y Chen, W Chen, PK Liaw, K An Materials & Design 219, 110820, 2022 | 24 | 2022 |
| Additive manufacturing of defect-free TiZrNbTa refractory high-entropy alloy with enhanced elastic isotropy via in-situ alloying of elemental powders S Mooraj, G Kim, X Fan, S Samuha, Y Xie, T Li, JS Tiley, Y Chen, D Yu, ... Communications Materials 5 (1), 14, 2024 | 16 | 2024 |
| 1564P Clinical pathway implications and real-world characteristics and outcomes for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first line … G Kim, P Cockrum, S Arndorfer, A Surinach Annals of Oncology 31, S953-S954, 2020 | 8 | 2020 |
| PCN16 IMPACT OF TREATMENT SEQUENCE ON OVERALL SURVIVAL IN METASTATIC PANCREATIC CANCER PATIENTS TREATED WITH LIPOSOMAL IRINOTECAN IN THE REAL-WORLD SETTING GP Kim, A Surinach, FA Corvino, P Cockrum Value in Health 22, S58, 2019 | 8 | 2019 |
| Effect of phosphorus on the phase stability of a high refractory content powder-processed Ni‐base superalloy L Li, G Kim, W Chen, S Tin Metallurgical and Materials Transactions A 50, 5459-5475, 2019 | 4 | 2019 |
| Site preferences and ordering in Nb (Al1-xMx) 2 (M= Ni or Cu) ternary Laves phases G Kim, Q Gu, P Nash, W Chen Acta Materialia 208, 116733, 2021 | 3 | 2021 |
| 1513P Real-world treatment discontinuation patterns among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based … G Kim, A Surinach, S Wang, N Lamarre, P Cockrum Annals of Oncology 32, S1107-S1108, 2021 | 2 | 2021 |
| Real-World 30-day Readmission Patterns Among Commercially Insured Patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) GP Kim, A Surinach, P Cockrum VALUE IN HEALTH 25 (7), S310-S311, 2022 | 1 | 2022 |
| The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma P Bhatt, J Hirsch, P Cockrum, G Kim, G Dieguez Journal of Health Economics and Outcomes Research 11 (2), 161, 2024 | | 2024 |
| IBCL-461 A Budget-Impact (BI) Analysis of Tazemetostat for the Treatment of 3L+ Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States L Watson, O Harrison, P Cockrum, K Veazey, S Gaugris, G Kim Clinical Lymphoma Myeloma and Leukemia 24, S498-S499, 2024 | | 2024 |
| A Budget-Impact (BI) Analysis of Tazemetostat for the Treatment of 3L+ Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States L Watson, O Harrison, P Cockrum, K Veazey, S Gaugris, G Kim Clinical Lymphoma, Myeloma and Leukemia 24, S223, 2024 | | 2024 |
| CO32 Predictors of Overall Survival (OS) and Time to Next Treatment (TTNT) in Real-World Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Patients Who Received First-Line … S Dennen, M Silver, P Cockrum, GP Kim Value in Health 27 (6), S22, 2024 | | 2024 |
| CO37 Real-World 30-Day Readmission Patterns Among Commercially Insured Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MPDAC) GP Kim, A Surinach, P Cockrum Value in Health 25 (7), S310-S311, 2022 | | 2022 |
